Background {#sec1}
==========

The Brugada syndrome (BrS) is diagnosed by the presence of a coved-type ST-segment elevation (type 1 BrS pattern) in the right precordial leads on the electrocardiogram (ECG) that occurs either spontaneously or after administration of a sodium channel blocking agent, such as ajmaline ([@ref2]), which reveals the type 1 pattern. Patients with this pattern are at increased risk of sudden cardiac death (SCD) ([@ref2]). The arrhythmias are caused by the presence of an arrhythmogenic substrate (AS) usually found in the epicardial surface of the right ventricle (RV) ([@ref21]; [@ref39]), which can be eliminated by trans catheter radiofrequency (RF) ablation. Ajmaline can be used to fully visualize the extent of the AS and improve the success of the procedure ([@ref25]).

The true prevalence of BrS is currently unknown, as SCD may be the first clinical manifestation in affected individuals. Many patients display a wide degree of clinical variability, even among the same family. BrS is considered as an inherited autosomal dominant disease with incomplete penetrance ([@ref6]; [@ref21]; [@ref19]). Variants in the *SCN5A* gene are found in about 15--30% of BrS cases ([@ref16]). *SCN5A* mutations are found in a number of pathologies, such as arrhythmogenic right ventricular cardiomyopathy, atrial standstill type 1, atrial fibrillation, left ventricular noncompaction, dilated cardiomyopathy, long QT syndrome type 3, sick sinus syndrome type 2, idiopathic ventricular fibrillation, and heart block type 1A ([@ref13]; [@ref38]; [@ref20]), making it difficult to predict a phenotype from novel variants within *SCN5A*. In the case of BrS, *SCN5A* variants are associated with a loss of function of the voltage-gated sodium channel subunit (Na~V~1.5) ([@ref10]; [@ref28]; [@ref9]).

Although a significant enrichment in rare coding variations in patients versus controls was observed only for the *SCN5A* gene by burden test ([@ref18]), genetic mutations are still not detected in the majority of BrS patients ([@ref30]), making BrS genetically elusive in many cases. In addition, the importance of genetic background has been highlighted in different studies, questioning Mendelian inheritance and proposing more complex oligogenic models ([@ref4]; [@ref10]). Better understanding of the genetics of BrS could assist clinicians in patient risk assessment, especially because ajmaline tests might have a low, but present, false negative rate ([@ref32]). However, research studies are limited by the lack of understanding of the human genetics in BrS. In the present study, we report a family with a heterozygous variant NM_198056:c.4894C\>T (p.Arg1632Cys) in the *SCN5A* gene. This variant has only been described twice before, once in a single patient with a complex arrhythmogenic phenotype ([@ref22]) and once in two siblings with vastly different phenotypes ([@ref11]). Thus, the phenotype associated with the variant described herein is uncertain in the current literature. In the present study, we report for the first time the genotype-phenotype correlation in several individuals, providing the strongest evidence to-date as to the possible effects of this variant.

Case Presentations {#sec2}
==================

The proband is a 32-year-old male of Italian origin with a history of syncope and hypothyroidism treated with substitutive levothyroxine. He performed an arrhythmogenic evaluation after a routine ECG (performed for known hypothyroidism) revealed a type 1 BrS pattern ([Figure 1](#fig1){ref-type="fig"}). Thus, the proband underwent electrophysiological study (EPS), which was negative. The patient received ajmaline to reveal the full extent of the AS prior to substrate catheter ablation ([Figure 2](#fig2){ref-type="fig"}).

![Electrocardiograms of proband and family members at baseline and after ajmaline challenge. Proband's father (II-7), proband (III-3), and proband's youngest sister (III-6) exhibit the BrS type 1 pattern after ajmaline administration, confirming the BrS diagnosis. Proband's second eldest sister (III-2) and brothers (III-4 and III-5) are ajmaline negative.](fphys-10-00666-g001){#fig1}

![Arrhythmogenic substrate characterization in Proband and Father. Electrocardiogram (left) demonstrates the type 1 BrS pattern after ajmaline administration, confirming the diagnosis. Potential duration map after ajmaline infusion (center) reveals the full extent of the arrhythmogenic substrate. The area of the substrate exhibiting potential durations at least 160 ms in duration is denoted by the "marked area" and is 13.7 cm^2^ for Proband and 16.6 cm^2^ for Proband's father. The duration of fragmented potentials (right) were prolonged and measured 272 ms for Proband and 325 ms for Proband's father.](fphys-10-00666-g002){#fig2}

Genetic Studies {#sec3}
---------------

Genetic testing was performed on peripheral blood-extracted genomic DNA with massive parallel sequencing (NGS) using Illumina TruSight Cardio enrichment and MiSeq platform. NGS yielded a coverage \>20X in 99.6% targeted regions and an average depth = 279X. Variants were called exploiting both commercial and in-house pipelines based one BWA, Smith-Waterman Algorithm, Freebayes, SnpSift-SnpEFF, MiSeq reporter. Sixteen BrS genes were analyzed: *CACNA1C, CACNA2D1, CACNB2, GPD1L, HCN4, KCND2, KCND3, MOG1, PKP2, RANGRF, SCN10A, SCN1B, SCN2B, SCN3B, SCN5A*, and *TRPM4*. Variants with a minor allele frequency \> 0.01 according to ExAC database and synonymous or intronic variants if not reported as pathogenic were filtered out.

The NM_198056:c.4894C\>T (p.Arg1632Cys) variant identified by NGS in the *SCN5A* gene was confirmed by Sanger sequencing using standard protocols ([@ref17]) and the following primers: Forward_GCACAGTGATGCTGGCTGGAA Reverse_GCAGAGTGGGGTCGCAGTAGG ([Figure 3](#fig3){ref-type="fig"}).

![Identification of the c. 4894C\>T (p.Arg1632CyS) missense mutation in the *SCN5A* gene. NGS paired-end reads loaded in the IGV genome browser. The arrow indicates the position of the single nucleotide variation in *SCN5A* gene in the proband **(A)** compared to a wild type control sample **(B)**. *SCN5A* gene is in the reverse orientation on the chromosome. Sanger sequencing electropherogram confirm the presence of the variants in the proband **(C)** and the absence in a wild type control **(D)**.](fphys-10-00666-g003){#fig3}

Assessment of Family Members {#sec4}
----------------------------

The proband's father is a 64-year-old male diagnosed at the age of 55 with arterial hypertension (pharmacologically treated with ACE inhibitors, successfully) and binodal heart disease. He came to our attention for familial history of BrS (in his son, the proband: see family tree, [Figure 4](#fig4){ref-type="fig"}). He received arrhythmologic evaluation by his family doctor, who recommended ajmaline challenge ([Figure 1](#fig1){ref-type="fig"}, [Table 1](#tab1){ref-type="table"}) and an EPS. The results of both of these exams were positive, so an implantable cardioverter device was implanted. After a couple of months, he underwent both binodal disease and BrS arrhythmogenic substrate ablation with a technique based on a transcatheterial application of radiofrequency ([Figure 2](#fig2){ref-type="fig"}). Both these procedures were successful and without any operative or postoperative complications. It is interesting that after the two ablations, the arterial hypertension improved, requiring a lesser dosage of antihypertensive drugs that he had taken for the previous 8 years. He underwent genetic counseling and was advised to undergo genetic testing for BrS. This test was performed on peripheral blood-extracted genomic DNA and sought only the heterozygous variant NM_198056:c.4894C\>T (p.Arg1632Cys) in the *SCN5A* gene. This test was positive, confirming a paternal origin for the variant discovered in the proband. The mother had also been genetically tested, due to the consanguinity with her husband, and she was negative for the variant found in her son.

![Family pedigree. Proband identified with arrow. Square: male; circle: female; slash: deceased; grayed: clinically affected by Brugada syndrome; star: molecularly confirmed *SCN5A* variant; star with slash: genetic test for *SCN5A* variant performed but negative.](fphys-10-00666-g004){#fig4}

###### 

Electrocardiogram parameters at baseline and after ajmaline administration, results of electrophysiological study and genetic testing.

          Baseline   Ajmaline   EPS   *SCN5A* variant                                     
  ------- ---------- ---------- ----- ----------------- ---- ----- ----- ----- ---------- -----
  II-7    68         290        95    410               72   365   138   510   Positive   Yes
  III-2   63         186        85    365               69   234   111   401   Negative   No
  III-3   88         220        110   420               --   --    --    --    Negative   Yes
  III-4   67         170        107   402               85   222   120   450   Negative   No
  III-5   44         181        106   390               59   250   125   445   Negative   Yes
  III-6   69         244        103   430               75   330   122   485   Negative   Yes

Proband's eldest sister (III-1) is 36 years old and asymptomatic. Her medical history is unremarkable and negative for arterial hypertension and binodal disease. However, she was referred for both ajmaline challenge and EPS due to a family history of BrS. She refused both of these procedures but accepted to undergo genetic testing to seek the heterozygous variant NM_198056:c.4894C\>T (p.Arg1632Cys) in the *SCN5A* gene. The result was positive.

Proband's second eldest sister (III-2) is a 35-year-old asymptomatic individual with an unremarkable medical history. The clinical arrhythmological evaluation was negative for arterial hypertension and binodal disease. However, she, like her sister, was referred for both ajmaline challenge and EPS due to family history of BrS. Both of these tests were negative ([Figure 1](#fig1){ref-type="fig"}). She also underwent genetic testing to seek the heterozygous variant NM_198056:c.4894C\>T (p.Arg1632Cys) in the *SCN5A* gene, which was negative.

Proband's eldest brother (III-4) is 33 years old and has an unremarkable medical history. The clinical arrhythmological evaluation was negative for both arterial hypertension and binodal disease. However, he, like his siblings, was referred for both ajmaline challenge and EPS due to family history of BrS. Both of these tests were negative ([Figure 1](#fig1){ref-type="fig"}), as was a genetic test for the *SCN5A* variant found in his family members.

Proband's youngest brother (III-5) is a 22-year-old male affected by allergic asthma, vitiligo, and insulin-dependent diabetes with onset in a pediatric age. No antibodies dosage was available at the time of genetic counseling, but the association with vitiligo suggests an autoimmune pathogenesis ([@ref15]). The patients suffered from recurrent lipothimic episodes, initially thought to be related only to type 1 diabetes. A 12-lead ECG performed because of family history raised the suspicion of BrS. The patient was then referred for EPS, ajmaline challenge, and genetic counseling. The EPS and ajmaline challenge were both negative ([Figure 1](#fig1){ref-type="fig"}). Genetic testing seeking the familial variant confirmed this patient harbors the paternally inherited heterozygous variant NM_198056:c.4894C\>T (p.Arg1632Cys) in the *SCN5A* gene. This patient has not performed any genetic testing to assess whether his diabetes could be considered syndromic or not.

Proband's youngest sister (III-6) is 28 years old with a medical history of autoimmune urticaria, autoimmune thyroiditis, and low blood pressure since a pediatric age. She experienced both lypothymic and syncopal episodes during fever and sometimes without fever as well. The arrhythmogenic evaluation performed because of her family history was negative for evidence of major arrhythmias or binodal disease. Considering her father's condition, a 12-lead ECG was performed, which raised the suspicion of BrS. Therefore, an ajmaline challenge was performed and confirmed the BrS diagnosis ([Figure 1](#fig1){ref-type="fig"}). An EPS was performed, but the patient was not inducible. This patient was then found to be positive for the same variant in *SCN5A* that was discovered in her father.

*In Silico* Predictions and Variant Classification {#sec5}
--------------------------------------------------

Several prediction tools were used to clarify the significance of the *SCN5A* variant: VarSome genetic database, SIFT, Polyphen2, Mutation Taster, AlignGVGD, and Provean. All of these softwares supported a damaging effect for the p.Arg1632Cys substitution. The Genomic Evolutionary Rate Profiling (GERP) value was noted, which is defined by VarSome as "a conservation score calculated by quantifying substitution deficits across multiple alignments of orthologues using the genomes of 35 mammals. It ranges from −12.3 to 6.17, with 6.17 being the most conserved" ([@ref8]). The GERP score for the *SCN5A* variant described herein was 4.5399. According to [@ref7], no families in which the c.4894C\>T heterozygous variant in the *SCN5A* gene segregates are provided to date (last update February 18, 2018). The allele frequency is 1: 113,644 in the general population (2019).

The c.4894C\>T variant was classified as likely pathogenic according to ACMG criteria ([@ref26]):

-   PM1: Located in a mutational hot spot and/or critical and well-established functional domain (in this case S4 voltage sensor in domain IV)

-   PM2: Extremely low frequency in general population (1/113,644 according to gnomAD) ([@ref12]).

-   PM5: Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before: the p.R1632H was previously reported and determined to affect channel function by functional studies ([@ref3]; [@ref14]).

-   PP3: Multiple lines of computational evidence support a deleterious effect on the gene or gene product

-   PP1: Cosegregation with disease in multiple affected family members in a gene definitively known to cause the disease

Discussion {#sec6}
==========

In the present study, we report the genotype-phenotype correlation in the largest family to-date with this heterozygous variant in the *SCN5A* gene. This study not only underlines the importance of genetic testing to identify family members who require preventive interventions, highlighting its clinical importance.

Since sudden cardiac death may be the first symptom with which a BrS patient presents, preventive interventions are instrumental in saving these lives. Genetic testing is a noninvasive, and thus safe and painless, method for family member risk stratification. Thus, understanding better the genetics of BrS not only can help create better disease models but it also has a significant clinical impact.

The *SCN5A* variant described herein is currently, as of the time of this writing, of unknown significance in the commonly relied upon database VarSome ([@ref33]). *In silico* studies predicted this variant to be damaging, because it is located in a voltage sensitive domain (VSD): a region crucial for the correct function of the Na~V~1.5 protein ([@ref35]). The activity of the Na~V~1.5 channel protein is controlled by a VSD ([@ref24]) using the positive charges of both lysine and arginine residues. Mutations involving these amino acids have been demonstrated by other groups to reduce the steepness of voltage-dependent gating of the Na^+^ channel. Additionally, these particular kinds of mutations can generate gating pore currents different from the central ionic current, resulting in deep modifications of the Na~V~1.5 gating property ([@ref31]).

The clinical data in the present study support these *in silico* predictions and strengthen the hypothesis that this variant is likely pathogenic, as classified according to ACMG criteria ([@ref26]) (see Case Presentations). Additionally, a recently published meta-analysis investigating the prognosis and risk stratification of *SCN5A* variants in BrS concluded that patients harboring an *SCN5A* variant were at higher risk of arrhythmic events ([@ref37]), supporting our previous findings ([@ref29]).

This variant has been previously described in a single patient who experienced a syncopal episode during exercise and who presented with atrial tachycardia, sinus node dysfunction, and BrS ([@ref22]). Additionally, the same variant has been described in a brother and sister exhibiting vastly different phenotypes ([@ref11]). In that study, a negative T wave and right bundle branch block were observed in the brother, who also tested positive for BrS during a flecainide test. However, the sister was described as a "healthy carrier" who "exhibited a normal baseline and drug challenged ECG." The authors concluded that there was "no evidence that this variant co-segregated with the disease." It is important to note that the authors additionally described two additional variants in the brother, and that the reader is left to assume that the drug challenge performed in the sister was a flecainide test. However, flecainide tests are not as powerful as ajmaline tests in unmasking the type 1 BrS pattern and may result in false negative results ([@ref36]).

It is significant to note for this study that the proband and his partner are consanguineous first cousins. Consanguinity increases the risk of inheriting pathogenic variants in both alleles of a disease gene, therefore leading to higher reproductive risk ([@ref27]). It seems likely that consanguinity plays a role for arrhythmogenic conditions as well ([@ref1]). However, it must be additionally noted that, in spite of the consanguinity, proband's mother tested negative for the familial variant. This finding increases the clinical significance of this variant for the disease that segregates in proband's family. However, consanguinity may lead to the transmission of a modifier SNPs which, when inherited homozygously, may act like a genetic trigger for arrhythmias in symptomatic family members.

One family member (patient III-5) harboring the R1632C variant in the *SCN5A* gene tested negative during an ajmaline challenge. Type 1 diabetes in this patient may have influenced the outcome of the ajmaline test. Type 1 diabetes causes an insulin depletion that can influence both ST elevation and ST-T wave changes ([@ref23]). Therefore, the BrS clinical picture can change dramatically as a direct effect of variations in both glucose and insulin concentrations ([@ref34]). However, further studies are needed to better understand the relationship between BrS and diabetes.

Concluding Remarks {#sec7}
==================

This study provides the most convincing evidence to-date for the genotype/phenotype relationship for the NM_198056:c.4894C \> T (p.Arg1632Cys) variant in the *SCN5A* gene. However, other mechanisms may complicate the genotype/phenotype correlation, including genetic background and particularly the presence of modifier polymorphisms. Further studies in larger groups of patients are therefore warranted to confirm these findings. Genetic testing is a valuable tool to identify at-risk family members and implement preventive interventions. Functional studies are warranted to better understand the molecular pathologies that result from this variant.
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